Melatonin protects against amyloid-β-induced impairments of hippocampal LTP and spatial learning in rats

Synapse

Volumn 67, Issue 9, 2013, Pages 626-636

  Liu, Xiao Jie ^a,b   Yuan, Li ^a   Yang, Dong ^a   Han, Wei Na ^a   Li, Qing Shan ^a   Yang, Wei ^a   Liu, Qing Song ^b   Qi, Jin Shun ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Amyloid protein; Local field potential; Long term potentiation; Melatonin; Morris water maze

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; MELATONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; INJECTION; LATENT PERIOD; LEARNING DISORDER; LONG TERM POTENTIATION; MALE; MAZE TEST; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; RAT; SPATIAL LEARNING; STEREOTACTIC DEVICE; SWIMMING; THETA RHYTHM; TREATMENT DURATION; WORKING MEMORY;

AMYLOID Β-PROTEIN; LOCAL FIELD POTENTIAL; LONG-TERM POTENTIATION; MELATONIN; MORRIS WATER MAZE;

AMYLOID BETA-PEPTIDES; ANIMALS; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MELATONIN; MEMORY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84880574849     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21677     Document Type: Article

References (87)

1. Abe M, Itoh MT, Miyata M, Ishikawa S, Sumi Y. 1999. Detection of melatonin, its precursors and related enzyme activities in rabbit lens. Exp Eye Res 68:255-262.
2. Abramov AY, Duchen MR. 2005. The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philos Trans R Soc Lond B Biol Sci 360:2309-2314.
3. Alkam T, Nitta A, Mizoguchi H, Itoh A, Nabeshima T. 2007. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 180:139-145.
4. Bland BH, Declerck S, Jackson J, Glasgow S, Oddie S. 2007. Septohippocampal properties of N-methyl-D-aspartate-induced theta-band oscillation and synchrony. Synapse 61:185-197.
5. Bland BH, Oddie SD. 2001. Theta band oscillation and synchrony in the hippocampal formation and associated structures: The case for its role in sensorimotor integration. Behav Brain Res 127:119-136.
6. Bliss TV, Collingridge GL. 1993. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 361:31-39.
7. Butterfield DA, Boyd-Kimball D. 2005. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703:149-156.
8. Chen QS, Kagan BL, Hirakura Y, Xie CW. 2000. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 60:65-72.
9. Chen YC, Sheen JM, Tain YL, Chen CC, Tiao MM, Huang YH, Hsieh CS, Huang LT. 2012. Alterations in NADPH oxidase expression and blood-brain barrier in bile duct ligation-treated young rats: Effects of melatonin. Neurochem Int 60:751-758.
10. Cheng SY, Trombetta LD. 2004. The induction of amyloid precursor protein and alpha-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione. Toxicol Lett 146:139-149.
11. Cheung RT. 2003. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 34:153-160.
12. Cheung RT, Tipoe GL, Tam S, Ma ES, Zou LY, Chan PS. 2006. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res 41:337-343.
13. Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, Misiti F. 2006. Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: An intriguing role for methionine 35. Biochem Biophys Res Commun 342:206-213.
14. Colell A, Fernandez A, Fernandez-Checa JC. 2009. Mitochondria, cholesterol and amyloid beta peptide: A dangerous trio in Alzheimer disease. J Bioenerg Biomembr 41:417-423.
15. Collins DR, Davies SN. 1997. Melatonin blocks the induction of long-term potentiation in an N-methyl-D-aspartate independent manner. Brain Res 767:162-165.
16. Cooke SF, Bliss TV. 2006. Plasticity in the human central nervous system. Brain 129(Pt 7):1659-1673.
17. Crouch PJ, Barnham KJ, Duce JA, Blake RE, Masters CL, Trounce IA. 2006. Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. J Neurochem 99:226-236.
18. Ding H, Schauerte JA, Steel DG, Gafni A. 2012. Beta-amyloid (1-40) peptide interactions with supported phospholipid membranes: A single-molecule study. Biophys J 103:1500-1509.
19. Dragicevic N, Copes N, O'Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, Tan J, Cao C, Olcese JM, Arendash GW, Bradshaw PC. 2011. Melatonin treatment restores mitochondrial function in Alzheimer's mice: A mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 51:75-86.
20. Ersahin M, Toklu HZ, Cetinel S, Yuksel M, Yegen BC, Sener G. 2009. Melatonin reduces experimental subarachnoid hemorrhage-induced oxidative brain damage and neurological symptoms. J Pineal Res 46:324-332.
21. Feng Z, Qin C, Chang Y, Zhang JT. 2006. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 40:101-109.
22. Ferreira ST, Vieira MN, De Felice FG. 2007. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59:332-345.
23. Frautschy SA, Cole GM. 2010. Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol 41:392-409.
24. Freir DB, Costello DA, Herron CE. 2003. A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J Neurophysiol 89:3061-3069.
25. Guo F, Jing W, Ma CG, Wu MN, Zhang JF, Li XY, Qi JS. 2010. [Gly(14)]-humanin rescues long-term potentiation from amyloid beta protein-induced impairment in the rat hippocampal CA1 region in vivo. Synapse 64:83-91.
26. Ha JS, Sung HY, Lim HM, Kwon KS, Park SS. 2012. PI3K-ERK1/2 activation contributes to extracellular H2O2 generation in amyloid beta toxicity. Neurosci Lett 526:112-117.
27. Hamel E, Nicolakakis N, Aboulkassim T, Ongali B, Tong XK. 2008. Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp Physiol 93:116-120.
28. Han WN, Holscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS. 2013. Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging 34:576-588.
29. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297:353-356.
30. Ionov M, Burchell V, Klajnert B, Bryszewska M, Abramov AY. 2011. Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity. Neuroscience 180:229-237.
31. Itkin A, Dupres V, Dufrene YF, Bechinger B, Ruysschaert JM, Raussens V. 2011. Calcium ions promote formation of amyloid beta-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One 6:e18250.
32. Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST. 2004. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 37:55-70.
33. Kanski J, Aksenova M, Schoneich C, Butterfield DA. 2002a. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. Free Radic Biol Med 32:1205-1211.
34. Kanski J, Varadarajan S, Aksenova M, Butterfield DA. 2002b. Role of glycine-33 and methionine-35 in Alzheimer's amyloid beta-peptide 1-42-associated oxidative stress and neurotoxicity. Biochim Biophys Acta 1586:190-198.
35. Kwon KJ, Kim HJ, Shin CY, Han SH. 2010. Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein kinase pathways. J Clin Neurol 6:127-137.
36. Kwon KJ, Kim JN, Kim MK, Lee J, Ignarro LJ, Kim HJ, Shin CY, Han SH. 2011. Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: A possible role in neuroprotection. J Pineal Res 50:110-123.
37. Leszkowicz E, Kusmierczak M, Matulewicz P, Trojniar W. 2007. Modulation of hippocampal theta rhythm by the opioid system of the pedunculopontine tegmental nucleus. Acta Neurobiol Exp (Wars) 67:447-460.
38. Li LM, Liu QH, Qiao JT, Zhang C. 2009. Abeta(31-35)-induced neuronal apoptosis is mediated by JNK-dependent extrinsic apoptosis pathway. Neurosci Bull 25:361-366.
39. Li WZ, Li WP, Huang DK, Kan HW, Wang X, Wu WY, Yin YY, Yao YY. 2012. Dexamethasone and Abeta(2)(5)-(3)(5) accelerate learning and memory impairments due to elevate amyloid precursor protein expression and neuronal apoptosis in 12-month male rats. Behav Brain Res 227:142-149.
40. Lisman J. 2010. Working memory: The importance of theta and gamma oscillations. Curr Biol 20:R490-R492.
41. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. 1999. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 84:323-327.
42. Logothetis NK. 2003. The underpinnings of the BOLD functional magnetic resonance imaging signal. J Neurosci 23:3963-3971.
43. Maat-Schieman ML, Yamaguchi H, van Duinen SG, Natte R, Roos RA. 2000. Age-related plaque morphology and C-terminal heterogeneity of amyloid beta in Dutch-type hereditary cerebral hemorrhage with amyloidosis. Acta Neuropathol 99:409-419.
44. Mattson MP. 2004. Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
45. Misiti S, Anastasi E, Sciacchitano S, Verga Falzacappa C, Panacchia L, Bucci B, Khouri D, D'Acquarica I, Brunetti E, Di Mario U, Toscano V, Perfetti R. 2005. 3, 5, 3'-Triiodo-L-thyronine enhances the differentiation of a human pancreatic duct cell line (hPANC-1) towards a beta-cell-Like phenotype. J Cell Physiol 204:286-296.
46. Molter C, O'Neill J, Yamaguchi Y, Hirase H, Leinekugel X. 2012. Rhythmic modulation of theta oscillations supports encoding of spatial and behavioral information in the rat hippocampus. Neuron 75:889-903.
47. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW. 2009. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 47:82-96.
48. Ozcan M, Yilmaz B, Carpenter DO. 2006. Effects of melatonin on synaptic transmission and long-term potentiation in two areas of mouse hippocampus. Brain Res 1111:90-94.
49. Pan B, Wang W, Zhong P, Blankman JL, Cravatt BF, Liu QS. 2011. Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J Neurosci 31:13420-13430.
50. Pan YF, Chen XR, Wu MN, Ma CG, Qi JS. 2010. Arginine vasopressin prevents against Abeta(25-35)-induced impairment of spatial learning and memory in rats. Horm Behav 57:448-454.
51. Patil S, Sheng L, Masserang A, Chan C. 2006. Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett 406:55-59.
52. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F. 1994. Melatonin: A peroxyl radical scavenger more effective than vitamin E. Life Sci 55:PL271-PL276.
53. Pratico D. 2008. Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 29:609-615.
54. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. 2000. Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48:809-812.
55. Qi JS, Qiao JT. 2001. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 105:845-852.
56. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. 2012. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 109:E2895-E2903.
57. Schilling T, Eder C. 2011. Amyloid-beta-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. J Cell Physiol 226:3295-3302.
58. Serrano-Pozo A, Mielke ML, Muzitansky A, Gomez-Isla T, Growdon JH, Bacskai BJ, Betensky RA, Frosch MP, Hyman BT. 2012. Stable size distribution of amyloid plaques over the course of Alzheimer disease. J Neuropathol Exp Neurol 71:694-701.
59. Shaftel SS, Griffin WS, O'Banion MK. 2008. The role of interleukin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J Neuroinflammation 5:7.
60. Shen Y, Zhang G, Liu L, Xu S. 2007. Suppressive effects of melatonin on amyloid-beta-induced glial activation in rat hippocampus. Arch Med Res 38:284-290.
61. Shen YX, Wei W, Xu SY. 2002a. Protective effects of melatonin on cortico-hippocampal neurotoxicity induced by amyloid beta-peptide 25-35. Acta Pharmacol Sin 23:71-76.
62. Shen YX, Xu SY, Wei W, Sun XX, Yang J, Liu LH, Dong C. 2002b. Melatonin reduces memory changes and neural oxidative damage in mice treated with D-galactose. J Pineal Res 32:173-178.
63. Stewart M, Fox SE. 1991. Hippocampal theta activity in monkeys. Brain Res 538:59-63.
64. Sultana R, Perluigi M, Butterfield DA. 2009. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: Role of Abeta in pathogenesis. Acta Neuropathol 118:131-150.
65. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M. 2008. Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104:683-695.
66. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. 2001. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54:565-568.
67. Vanderwolf CH. 1969. Hippocampal electrical activity and voluntary movement in the rat. Electroencephalogr Clin Neurophysiol 26:407-418.
68. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. 2000. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184-208.
69. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA. 1999. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res Bull 50:133-141.
70. Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ. 2012. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149:708-721.
71. Vertes RP, Kocsis B. 1997. Brainstem-diencephalo-septohippocampal systems controlling the theta rhythm of the hippocampus. Neuroscience 81:893-926.
72. Vorhees CV, Williams MT. 2006. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848-858.
73. Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS. 2005. Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci 22:2231-2237.
74. Wiechmann AF, Sherry DM. 2013. Role of melatonin and its receptors in the vertebrate retina. Int Rev Cell Mol Biol 300:211-242.
75. Wimo A, Prince MJ, International AsD. 2010. World Alzheimer Report 2010: The global economic impact of dementia. Alzheimer's Disease International.
76. Winson J. 1978. Loss of hippocampal theta rhythm results in spatial memory deficit in the rat. Science 201:160-163.
77. Wu MN, He YX, Guo F, Qi JS. 2008. Alpha4beta2 nicotinic acetylcholine receptors are required for the amyloid beta protein-induced suppression of long-term potentiation in rat hippocampal CA1 region in vivo. Brain Res Bull 77:84-90.
78. Xia W. 2001. Amyloid metabolism and secretases in Alzheimer's disease. Curr Neurol Neurosci Rep 1:422-427.
79. Xia W. 2003. Amyloid inhibitors and Alzheimer's disease. Curr Opin Investig Drugs 4:55-59.
80. Xiao XQ, Zhang HY, Tang XC. 2002. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 67:30-36.
81. Yan XZ, Qiao JT, Dou Y, Qiao ZD. 1999. Beta-amyloid peptide fragment 31-35 induces apoptosis in cultured cortical neurons. Neuroscience 92:177-184.
82. Ye L, Qiao JT. 1999. Suppressive action produced by beta-amyloid peptide fragment 31-35 on long-term potentiation in rat hippocampus is N-methyl-D-aspartate receptor-independent: It's offset by (-)huperzine A. Neurosci Lett 275:187-190.
83. Yoder RM, Pang KC. 2005. Involvement of GABAergic and cholinergic medial septal neurons in hippocampal theta rhythm. Hippocampus 15:381-392.
84. Zhang JF, Qi JS, Qiao JT. 2009. Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo. Neurobiol Learn Mem 91:226-234.
85. Zhang JM, Wu MN, Qi JS, Qiao JT. 2006. Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. Synapse 60:307-313.
86. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. 2003. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35:125-130.
87. Zucker RS, Regehr WG. 2002. Short-term synaptic plasticity. Ann Rev Physiol 64:355-405.